← Back to patent-cliff list
KL-130008
Tier C — Watch / tradeKL-130008
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：JAK
Indications (approved)：Rheumatoid arthritis, Alopecia areata
Regional status
US
Phase II
2024-04-01
EU
-
China
Phase II
2021-11-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of KL-130008?
Approved indications include: Rheumatoid arthritis, Alopecia areata.
When does the KL-130008 patent expire?
No public expiry year is available for KL-130008 yet; this page updates once verified.
How do I get a quote for KL-130008 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21